TickerSpark Feed

ipo

Everything tagged "ipo" across the TickerSpark archives.

The Daily Briefing · Free

A new stock idea, every evening.

One stock worth watching each weekday, free in your inbox.

Creates a free TickerSpark account — newsletter included.

Daily market recap + weekly preview. One-click unsubscribe in every email.

What to Watch as BlossomHill Therapeutics Prices Its NASDAQ IPO
IPOBLSM

What to Watch as BlossomHill Therapeutics Prices Its NASDAQ IPO

BlossomHill Therapeutics, Inc. (NASDAQ: BLSM) is expected to list on 2026-08-07 at a price range of $15.00 to $17.00 per share. The company is offering 7,812,500 shares, implying a market cap of $152,734,375 if priced at the midpoint assumptions provided. The bull case is a focused oncology pipeline with named clinical programs and a seasoned drug-discovery team. The bear case is straightforward: no product revenue, rising losses, and a going-concern warning if it cannot raise more capital.

Aug 4, 20265 MIN
Eos Energy Enterprises IPO Preview: Storage Growth Meets Financing Risk
IPOEOSEW

Eos Energy Enterprises IPO Preview: Storage Growth Meets Financing Risk

Eos Energy Enterprises, Inc. is expected to list on NASDAQ on 2026-08-04, but the price range has not been disclosed. The company is already public, so the key event to watch is its latest equity financing and how investors respond to the Frontier-linked capital plan. Bulls will focus on rapid revenue growth and a large backlog; bears will focus on dilution, execution, and funding dependence.

Aug 4, 20266 MIN
Inside the Obsidian Therapeutics IPO: Reverse-Merger Setup, Risks, and Watchpoints
IPOOBX

Inside the Obsidian Therapeutics IPO: Reverse-Merger Setup, Risks, and Watchpoints

Obsidian Therapeutics, Inc. Common Stock (NASDAQ: OBX) is expected to list on 2026-08-04, but the price range has not been disclosed. The company is coming to market through an all-stock reverse merger with Galera Therapeutics rather than a traditional IPO. Bull case: a differentiated cell-therapy platform with strong strategic backing; bear case: no disclosed pricing, no commercial revenue, and heavy clinical risk.

Aug 4, 20265 MIN
On-Demand Research

Need research on a stock not covered here?

Generate AI research on any ticker — grades, price targets, and full analysis in minutes.

Open the Generator